ONO-2952

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H20ClFN2O2
Molecular Weight	398.858
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(C=CC(Cl)=C1)[C@@H]2N(CC3(CC3)C4=C2NC5=C4C(F)=CC=C5)C(C)=O

InChI

InChIKey=ZBQMTQGDBFZUBG-NRFANRHFSA-N

InChI=1S/C22H20ClFN2O2/c1-12(27)26-11-22(8-9-22)19-18-15(24)4-3-5-16(18)25-20(19)21(26)14-7-6-13(23)10-17(14)28-2/h3-7,10,21,25H,8-9,11H2,1-2H3/t21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H20ClFN2O2
Molecular Weight	398.858
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

C_max

Value	Dose	Analyte	Population
9.54 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
27.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
60.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
63.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
159 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
225 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1720 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
227 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
197 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
388 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
752 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
344 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
605 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1370 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
206 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
694 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1100 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1710 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4130 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7730 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
28700 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
9640 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1630 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3270 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6850 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4300 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7500 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
18700 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
42 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
37 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
42 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26249232/	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ONO-2952 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:54:32 GMT 2025` Edited by `admin` on `Mon Mar 31 20:54:32 GMT 2025`
Record UNII	ZH8CPX4YNB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1-((1'S)-1'-(4-CHLORO-2-METHOXYPHENYL)-5'-FLUORO-1',2',3',9'-TETRAHYDROSPIRO(CYCLOPROPANE-1,4'-(4H)PYRIDO(3,4-B)INDOL)-2'-YL)ETHANONE

Preferred Name

English

ONO-2952

Common Name

English

1-((1S)-1-(4-CHLORO-2-METHOXYPHENYL)-5-FLUORO-1,9-DIHYDROSPIRO(.BETA.-CARBOLINE-4,1'-CYCLOPROPAN)-2(3H)-YL)ETHANONE

Systematic Name

English

ETHANONE, 1-((1'S)-1'-(4-CHLORO-2-METHOXYPHENYL)-5'-FLUORO-1',2',3',9'-TETRAHYDROSPIRO(CYCLOPROPANE-1,4'-(4H)PYRIDO(3,4-B)INDOL)-2'-YL)-

Systematic Name

English

SPIRO(CYCLOPROPANE-1,4'-(4H)PYRIDO(3,4-B)INDOLE), 2'-ACETYL-1'-(4-CHLORO-2-METHOXYPHENYL)-5'-FLUORO-1',2',3',9'-TETRAHYDRO-, (1'S)-

Systematic Name

English

Code System Code Type Description

FDA UNII

ZH8CPX4YNB